Off-label, But Lucrative
By Nav Dhillon
Big pharma profits when doctors prescribe a drug for a disorder other than the one that earned FDA approval. The practice ranges from evidence-based to highly egregious.
One in five prescriptions written in the United States is for a drug that hasn’t been approved for what’s ailing the patient.
That factoid from the Agency for Healthcare Research and Quality website casts a shadow of doubt over many of the prescriptions known as “off-label.”
It’s when doctors prescribe a drug for a disorder other than the one that earned Food and Drug Administration (FDA) approval. They might, for example, order a diabetes drug for a patient who’s not diabetic but wants to lose weight.
Off-label prescribing is often appropriate, and...
Topics
-
ChatGPT Faces Competition as Bots Navigate Copyrights
|Meanwhile, high-quality data is costly and getting scarce, which impedes advances in generative AI -
Vertiv Pushed Back on A Recent Luckbox Story. Here is Our Response.
By Luckbox
|Vertiv’s points are well taken, however, they don’t ultimately change the overall analysis and outlook of the analysis. -
Databricks IPO: An AI Heavyweight with Nvidia’s Seal of Approval
|Data has been likened to gold in the new era of generative AI, which is one reason a potential Databricks IPO is so highly anticipated on Wall Street. -
Strong Economic Data Pushes Expected Rate Cut to Q3
|The bond rally might have to wait until late in the year -
Trump Media Part 2: How Traders Can Approach this Meme Stock
|Here is what to consider when evaluating the value of Trump Media & Technology Group -
Trump Media, Part 1: Risk Abounds in This Highly Volatile Listing
|Shares in the Trump Media & Technology Group appear to be setting up for a potential binary move in the wake of the 2024 presidential election -
Ford vs. General Motors
|Two venerable automakers face political and economic hassles. Are they good investments? -
It’s Not Easy Being Green
|Lawyers, lobbyists, legislators and lizards impede America’s transition to electric vehicles -
Less Than Electrifying
By Ed McKinley
|Range worries and sticker shock are slowing the growth of EV sales -
Retro Cool
By James Melton
|An upstart EV recalls a James Bond-like design equipped with a voice- activated cockpit -
Range Worry and Other EV Anxieties
By Ed McKinley
|An automotive journalist addresses the electric-vehicle market -
Adoption Issues
By James Melton
|Two experts assess EV appeal, environmental impact, jobs, and prices -
Fast-Charging Toyota
By James Melton
|The Japanese auto giant plans to jumpstart battery technology -
The Twelve Hottest New Cars of 2024
By James Melton
|From the practical to the aspirational, these new gas, hybrid and electric vehicles scorched their way to our shortlist -
Vertiv Holdings (VRT): A Q1 Earnings Beat is Paramount
|Vertiv Holdings (VRT) looks well-positioned to capitalize on the emerging AI revolution. But after a subpar Q4 2023 earnings report, the company still has a lot to prove heading into… -
Why Q1 Earnings Season is So Important for the Regional Banks
|The continued slide in shares of New York Community Bancorp (NYCB) shows the regional banking crisis isn’t yet resolved -
Synopsys (SNPS)-ANSYS (ANSS) Merger: Two Key Partners of Nvidia Unite
|Nvidia announced at its annual GPU Technology Conference (GTC) that it is expanding its partnership with ANSYS (ANSS) -
Inevitable Evolution
By Ed McKinley
|Luckbox expects the march toward wider EV adoption will continue nearly unabated -
A Trump Reelection Could Shake Up the Energy Industry
|If Donald Trump is reelected for a second term in November, the energy sector could experience a shake up due to renewed support for traditional fossil fuel companies and a…